-
ROLE OF REAL-WORLD EVIDENCE IN SUPPORTING AND VALIDATING CROSSOVER ADJUSTMENTS OF OVERALL SURVIVAL IN ONCOLOGY TRIALS: A SYSTEMATIC LITERATURE REVIEW OF HEALTH TECHNOLOGY ASSESSMENTS OF TREATMENTS FOR SELECTED TUMORS
Mar 18, 2026, 21:38 PM -
A DECISION TREE ESTIMATING TOTAL COST OF CARE USING EXPOSURE-ADJUSTED DISCONTINUATION: CAPSAICIN 8% VERSUS ORAL TREATMENTS FOR PAINFUL DIABETIC NEUROPATHY IN THE UNITED STATES
Mar 18, 2026, 21:38 PM -
COST OF HEALTHCARE IN PATIENTS NEWLY DIAGNOSED WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS
Mar 18, 2026, 21:38 PM -
ESTIMATING THE COST OF ORPHAN DRUG TREATMENT FROM THE PERSPECTIVE OF MEXICO'S PUBLIC SECTOR
Mar 18, 2026, 21:38 PM -
EFFECT OF ANTIHYPERTENSIVE USE ON FALL RISK
Mar 18, 2026, 21:38 PM -
USE OF A NEW INSTRUMENT TO ASSESS HEALTH-RELATED QUALITY OF LIFE IN CHILDREN 0-3 YEARS OF AGE DURING HOSPITALIZATION DUE TO ROTAVIRUS GASTROENTERITIS IN THE US
Mar 18, 2026, 21:38 PM -
INTERPRETABLE MACHINE LEARNING TO PREDICT CATASTROPHIC HEALTH EXPENDITURE RISK IN CHINA: EVIDENCE FROM NATIONALLY REPRESENTATIVE SURVEY DATA
Mar 18, 2026, 21:38 PM -
SAFETY OF SEPIAPTERIN AND PEGVALIASE FOR THE TREATMENT OF PHENYLKETONURIA (PKU): A SIMULATED TREATMENT COMPARISON (STC)
Mar 18, 2026, 21:38 PM -
INCORPORATING REAL-WORLD EVIDENCE (RWE) USING A REAL-TIME AI-ASSISTED LIVING SYSTEMATIC LITERATURE REVIEW (REAL-SLR) AUGMENTS TRADITIONAL SLRS: CASE STUDY IN NON-SMALL-CELL LUNG CANCER (NSCLC)
Mar 18, 2026, 21:38 PM -
UNCOVERING EVIDENCE GAPS IN THE CLINICAL, ECONOMIC, AND HUMANISTIC IMPACT OF DUCHENNE MUSCULAR DYSTROPHY: A COMPREHENSIVE LITERATURE REVIEW
Mar 18, 2026, 21:38 PM -
NATIONWIDE COVID-19 TESTING PATTERNS AND DISPARITIES IN POSITIVITY AND ANTIVIRAL TREATMENT IN A U.S. RETAIL PHARMACY CHAIN, SEPTEMBER-DECEMBER 2025
Mar 18, 2026, 21:38 PM -
HOW REPRESENTATIVE ARE LICENSABLE DATASETS COMPARED TO THEIR SOURCE POPULATION
Mar 18, 2026, 21:38 PM -
INFLUENCING FACTORS ON THE APPROVAL LAG FOR INNOVATIVE DRUGS IN CHINA
Mar 18, 2026, 21:38 PM -
FROM RETRIEVAL TO VERDICT: A HYBRID LLM PIPELINE FOR EVALUATING MEDICAL AND ECONOMIC CLAIMS
Mar 18, 2026, 21:38 PM -
METHODOLOGICAL CHARACTERISTICS OF PHARMACOGENOMICS-INTEGRATED AI CLINICAL DECISION SUPPORT SYSTEMS (AI-CDSS): A SYSTEMATIC REVIEW
Mar 18, 2026, 21:38 PM -
TEPROTUMUMAB VERSUS INTRAVENOUS METHYLPREDNISOLONE ALONE, AND IN COMBINATION WITH MYCOPHENOLATE MOFETIL, FOR MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE: A MATCHING-ADJUSTED INDIRECT COMPARISON
Mar 18, 2026, 21:38 PM -
THE ECONOMIC BURDEN ON FAMILIES OF CHILDREN WITH TYPE 1 SPINAL MUSCULAR ATROPHY IN BRAZIL
Mar 18, 2026, 21:38 PM -
PROVISIONAL PRICING IN MEDICINE POLICY: GLOBAL BENCHMARKING
Mar 18, 2026, 21:38 PM -
FORMULARY EXCLUSIONS AND NON-ADHERENCE TO DISEASE-MODIFYING THERAPIES FOR MULTIPLE SCLEROSIS IN MEDICARE PART D
Mar 18, 2026, 21:38 PM -
USE OF PRIOR AUTHORIZATION, STEP THERAPY, AND QUANTITY LIMITSIN THE UNITED STATES: A NATIONAL PHARMACY CLAIMS ANALYSIS
Mar 18, 2026, 21:38 PM
